Moreover, this study is the first to report a molecular docking-based workflow meant to investigate the interactions of the ten components of CEO with key druggable protein targets—EGFR1, VEGFR2, PI3Kα, MEK1, AKT/PKB, mTOR, Bcl-XL, and Bcl-2—associated with cancer cell proliferation and survival, thus providing valuable insights into the potential protein-targeted mechanisms underlying the observed anticancer activity. This evidence concerns the gene AKT1 and cancer.